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Genetic control of hematopoietic stem and progeni-
tor cell (HSPC) function is increasingly understood;
however, less is known about the interactions spec-
ifying the embryonic hematopoietic niche. Here,
we report that 17b-estradiol (E2) influences produc-
tion of runx1+ HSPCs in the AGM region by antago-
nizing VEGF signaling and subsequent assignment
of hemogenic endothelial (HE) identity. Exposure
to exogenous E2 during vascular niche develop-
ment significantly disrupted flk1+ vessel maturation,
ephrinB2+ arterial identity, and specification of scl+
HE by decreasing expression of VEGFAa and down-
stream arterial Notch-pathway components; heat
shock induction of VEGFAa/Notch rescued E2-medi-
ated hematovascular defects. Conversely, repres-
sion of endogenous E2 activity increased somitic
VEGF expression and vascular target regulation,
shifting assignment of arterial/venous fate and HE
localization; blocking E2 signaling allowed venous
production of scl+/runx1+ cells, independent of arte-
rial identity acquisition. Together, these data suggest
that yolk-derived E2 sets the ventral boundary of
hemogenic vascular niche specification by antago-
nizing the dorsal-ventral regulatory limits of VEGF.
INTRODUCTION
Hematopoietic stem cells (HSCs) are characterized by a lifelong
ability to self-renew and give rise to each differentiated blood
lineage. In mice, the first definitive HSCs arise at embryonic
day 10.5 from hemogenic endothelium (HE) in the ventral wall
of the dorsal aorta in the aorta-gonad-mesonephros (AGM) re-
gion (Dzierzak and Speck, 2008). Whereas signaling cascadesDevethat control specification of arterial identity are well elucidated
(Lawson et al., 2001, 2002), less is known about the factors regu-
lating the dorsal/ventral limits of HE identity. Recent studies have
implicated several pathways in patterning the AGM and subse-
quent HSC emergence, acting in part via polarized expression
of signaling elements on the dorsal side (Clements et al., 2011;
Wilkinson et al., 2009). However, the mechanism by which these
signaling cascades integrate to specify the limits of HE remains
an open question, as does the identity of ventral-derived signals
(Jaffredo et al., 2013). Additionally, data from both zebrafish
(Burns et al., 2005; Kim et al., 2013) and mice (Robert-Moreno
et al., 2008) indicate that production of HSCs within arteries
may not be required for HE specification. Following niche assign-
ment, the transcription factor Runx1 is recognized for its critical
and highly conserved role in HSC development (North et al.,
2002; Okuda et al., 1996; Wang et al., 1996), where it is required
for HSCs to ‘‘bud’’ from HE (Chen et al., 2009). In zebrafish, he-
matopoietic stem and progenitor cells (HSPCs) first emerge in an
analogous region of the dorsal aorta between 30–36 hr postferti-
lization (hpf), and runx1mediates a similar role in their production
(Kissa and Herbomel, 2010). Our group has previously identified
regulators of vertebrate HSC development via an in vivo chemi-
cal screening approach in zebrafish (Goessling et al., 2009,
2011; North et al., 2007, 2009); in that screen, estrogens and es-
trogen-related compounds were found to have a potent impact
on the formation of runx1+ HSCs.
Estrogen is a cholesterol-derived steroid hormone synthe-
sized from testosterone by the enzyme CYP19A1 (Aromatase).
There are three primary forms of estrogen found in the verte-
brate phylum: estrone, estradiol, and estriol. 17b-Estradiol (E2),
commonly referred to as ‘‘estrogen,’’ is the most potent. Classi-
cally, E2 acts as a transcription factor upon binding to cyto-
plasmic nuclear hormone receptors, estrogen receptor 1 (Esr1;
ERa) or Esr2 (ERb), which subsequently translocate to the nu-
cleus and bind estrogen response elements (EREs) in regulatory
regions of estrogen-responsive genes (Heldring et al., 2007). In
zebrafish, because of a partial genome duplication, in addition
to esr1, there are two esr2 receptors: esr2a and esr2b (Menuetlopmental Cell 29, 437–453, May 27, 2014 ª2014 Elsevier Inc. 437
Figure 1. Exposure to E2 Impairs Formation of HSPCs in the AGM
(A) E2 exposure from five somites to 36 hpf decreased runx1/cmyb expression in the AGM (210/234).
(B) E2 diminished runx1:GFP+ cells in the AGM (34/39).
(C) FACS analysis of CD41:GFP embyros (representative samples shown) confirmed that E2 reduced HSCs.
(D) CD41:GFP was significantly decreased by E2 (n = 20, two-tailed t test, p < 0.001; error bars indicate SD).
(E) qPCR quantified reduced runx1 and cmyb expression by E2 (mean of triplicate experiments ± SEM; one-tailed t test runx **p < 0.01, cmyb *p < 0.05).
(F) The pan-Esr antagonist FULV blocked the effect of E2; the isomer 17a-estradiol (10 mM) had no effect (nR 30/treatment).
(legend continued on next page)
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protein-coupled receptor (GPER; also called GPR30) (Liu et al.,
2009; Revankar et al., 2005). Although the role of E2 in reproduc-
tive organ development is established (Wilson andDavies, 2007),
less is known of its impact on the formation of other organ
systems.
Endogenous E2 levels are highly variable during mammalian
gestation. E2 levels are low during early pregnancy but increase
throughout gestation, peaking just prior to delivery (Tulchinsky
et al., 1972). It is unclear whether the developing embryo
is exposed to increasing concentrations of E2; indeed, several
pieces of evidence suggest mechanisms are in place to limit
E2 exposure to the conceptus. Expression of 17b-hydroxyste-
roid dehydrogenase type 2, which degrades E2, varies between
umbilical arteries and veins and may protect the developing
embryo from deleterious effects of excess maternal E2 (Simard
et al., 2011). Surfeit estrogen can have a negative impact on
maintenance of pregnancy, indicating a need for careful control
over E2 levels during gestation (Mahendroo et al., 1997). Based
on the presumed importance of controlled E2 exposure during
embryogenesis, there are increasing concerns regarding the
presence of estrogenic substances in the environment. Diethyl-
stilbestrol (DES), a synthetic estrogen previously prescribed as
an antiabortifactant, was found to increase risk of vaginal and
cervical cancer, as well as male genital defects, in offspring
whose mothers took the drug (Harris and Waring, 2012).
Maternal hormonal use in the first trimester of pregnancy is asso-
ciated with increased risk of infant acute leukemia, indicating
in utero exposure to estrogenic compounds may influence fetal
hematopoietic homeostasis (Pombo-de-Oliveira et al., 2006).
As little is known about the impact of estrogens on hematopoie-
sis during embryogenesis, we sought to prospectively determine
the effect of E2 and related compounds on HSC formation.
Here, we demonstrate that exposure to excess E2 from early
somitogenesis until 24 hpf, the window of hemogenic endothe-
lial (HE) specification, significantly decreased the formation of
runx1+ AGM HSPCs. In contrast, later exposure, during HSC
specification and budding, enhanced HSPC number. HSPC
loss after early E2 exposure was mediated via esr2 and resulted
from a failure to specify HE in the dorsal aorta. Defects in
both VEGF and Notch signaling, required for the establish-
ment of arterial identity and hemogenic niche formation, were
noted following E2 treatment; hyperactivation of VEGF rescued
runx1 expression through induction of the Notch pathway, indi-
cating that disruption of this signaling cascade underlies the
observed hematovascular alterations. Exposure to xenoestro-
gens ethinylestradiol and genistein partially replicated E2-medi-
ated phenotypes, decreasing runx1+ HSPC expression and
altering vascular niche specification. Significantly, antagonism
of intrinsic estrogen signaling enhanced the expression and
regulatory function of VEGF, increasing the zone of scl+ HE
specification, independent of ephrinB2+ arterial assignment,
and enhancing the production of HSPCs. Together, these data(G) Estradiol EIA revealed that endogenous estrogens are present during hemat
triplicate experiments ± SEM; two-tailed t test, *p < 0.05).
(H) ERE:GFP fish show estrogenic activity in the AGM.
(I) GFP expression (as seen in H) was increased 1.57-fold upon E2 exposure (n =
The number of embryos with altered expression over the total number analyzed
Devesuggest endogenous E2 acts as a previously unappreciated
morphogen, opposing the action of VEGF to control the assign-
ment of the embryonic HE niche.
RESULTS
17b-Estradiol Decreases Formation of HSCs
E2 and estrogen-related compounds were identified in a prior
screen for modulators of HSC formation (North et al., 2007) (Fig-
ure S1A available online). To confirm and characterize the impact
of hormonal regulation on hematopoiesis, zebrafish embryos
were exposed to 17b-estradiol (E2) from five somites (12 hpf)
until 36 hpf, the window of hematopoietic initiation in zebrafish
(Figure S1B). Markedly decreased expression of the conserved
HSPC markers runx1 and cmyb was observed in the AGM after
E2 treatment relative to sibling controls (Figure 1A) by whole-
mount in situ hybridization (WISH); with the chorion intact, this
effect was dose dependent over a range of 0.1 to 10 mM E2 in
the fish water, whereas phenotypic changes were seen at
0.01 mM E2 with the chorion removed (Figure S1C). Using a
transgenic runx1-reporter line (Tg(runx1P1:EGFP)), E2-mediated
reduction in runx1+ cells was confirmed in vivo (Figure 1B);
fluorescence-activated cell sorting (FACS) quantification of the
CD41:GFP line (Tg(6.0itga2b:EGFP)), marking mature HSCs,
revealed a similar decrease (Figures 1C and 1D; p < 0.001).
These findings were corroborated by whole-embryo quantitative
PCR (qPCR) (Figure 1E; runx p < 0.01, cmyb p < 0.05). To deter-
mine if the effect of E2 was receptor mediated, embryos were
treated with a pan-Esr antagonist, Fulvestrant (FULV; 15 mM),
in the presence and absence of E2 (Figure 1F). Exposure to
FULV alone increased runx1/cmyb and restored expression in
the majority of E2-treated embryos. Identical results were
observed with ZK164015 (ZK; 10 mM) (Figure S2A). Notably,
exposure to 17a-estradiol, the inactive isomer of E2, did not
affect HSPCs (Figure 1F), nor did the GPER agonist, G1, or
antagonist, G15 (Figure S2A). Finally, no changes were observed
in the gross development of other major embryonic organ sys-
tems (Figure S1D), demonstrating that E2 acts via cytoplasmic
nuclear hormone receptors to impact HSPC formation during
this window of embryogenesis.
Zebrafish Possess Endogenous Estrogenic Activity and
the Ability to Respond to E2 Signaling
To examine endogenous E2 content during hematopoiesis,
a modified ELISA assay was performed. Zebrafish embryos
showed higher E2 levels early in development (0–48 hpf) than
in larval stages (72–120 hpf) (Figure 1G). The decrease in E2 con-
centration during embryogenesis suggested that endogenous
estrogen may be contained in the yolk; following manual deyolk-
ing at 18 hpf, E2 levels were found to be 4.7-fold higher in yolk
compared to the embryo body (p < 0.05). Consistent with
maternal contribution of E2, enzymes involved in E2 synthesis
were undetectable by qPCR until 20 hpf (Figure S2D). Asopoiesis; E2 was enriched 4.7-fold in the yolk versus body at 18 hpf (mean of
15, two-tailed t test, p < 0.05; error bars indicate SD).
is shown (bottom right).
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assessed. Whole-embryo qPCR confirmed published results
(Chandrasekar et al., 2010): esr1 was expressed at low levels
immediately after fertilization but increased starting at 12 hpf.
In contrast, esr2a and esr2b were more robustly expressed
immediately after fertilization and subsequently declined,
consistent with maternal deposition (Figure S2B); after 12 hpf,
expression of esr2a and esr2b increased, suggestive of embry-
onic transcriptional initiation. esr2a was previously shown to
be expressed ubiquitously via WISH during the time frame of he-
matopoietic development, whereas neither esr1 nor esr2b were
observed at detectable levels until >36 hpf (Bertrand et al.,
2007). To identify if hematovascular populations in the AGM
express esrs, we analyzed publicly available microarray data
(Weber et al., 2005): both endothelial cells and emerging HSPCs
express esrs to varying degrees, indicating that they can
respond to E2 regulation during embryogenesis (Figure S2C).
To determine if E2 signaling was active in the AGM, we exam-
ined activity in transgenic embryos expressing GPF under con-
trol of the E2 response element [Tg(5xERE:GFP)] (Gorelick and
Halpern, 2011). At 36 hpf, endogenous E2 activity was observed
over the yolk extension, with the strongest signal situated to the
ventral side of the embryo (Figure 1H). Addition of 10 mM E2
increased whole-embryo ERE:GFP levels 1.57-fold, as quanti-
fied by FACS, within the physiological range of estrogen activity
(Figure 1I; p < 0.05), and consistent with recent reports (Hao
et al., 2013); expression of vitellogenin-1 (vtg1), a classic estro-
gen target, showed a similar 2-fold induction (p < 0.001) (Fig-
ure S2E). ERE:GFP WISH revealed E2 activity over the yolk in
the ventral aspect of the trunk as early as 18 hpf (Figure S2F).
To ensure that GFP expression was due to endogenous E2
and to identify the receptor(s) responsible for the HSPC pheno-
type, we utilized morpholino (MO)-mediated knockdown. Injec-
tion of esr MOs (Froehlicher et al., 2009; Griffin et al., 2013;
Pang and Thomas, 2010) reduced ERE:GFP levels similarly to
ZK exposure (Figures S3A and S3B). No effects on HSPCs
were observed for esr1 knockdown (Figure 2A). Whereas injec-
tion of the esr2a MO increased runx1/cmyb expression, E2
remained capable of reducing HSPCs. esr2b knockdown had
only mild effects on HSPCs; however, coinjection of esr2a and
esr2b MOs blocked the effect of E2, indicating that these iso-
forms are the primary mediator of the HSPC phenotype. These
results were corroborated using receptor-selective compounds
for Esr1 (PPT [agonist] and MPP [antagonist]) and Esr2 (DPN
[agonist] and PHTPP [antagonist]) (Figure S3C; data not
shown). As microarray analysis indicated esr2a was present in
endothelium (Figure S2C), ERE:GFP activity was examined in
lmo2:dsRed embryos (Figure 2B). Occasional ERE:GFP+ cells
were embedded in the aortic vasculature of controls at 36 hpf,
and double-positive cell numbers increased following E2 expo-
sure; WISH indicated vascular (fli1+) localization and response
to E2-stimulation could be detected by 24 hpf (Figure S3E).
Strong E2-responsive ERE:GFP colocalization was also noted
in the kidney, ventral to the aortic vasculature and adjacent
to maternal yolk deposits, using the Tg(cdh17:mCherry) reporter
(Figure 2C); by WISH, kidney expression and E2 responsiveness
was observed at 24 hpf (Figure S3D). Together, these data indi-
cate E2 is present and can elicit receptor-mediated activity in the
AGM during hematovascular development.440 Developmental Cell 29, 437–453, May 27, 2014 ª2014 Elsevier InE2 Exposure Impairs Formation of the Hemogenic
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To determine how effects on HSPCs were mediated, we exam-
ined the impact of E2 exposure during two major developmental
milestones of HSC production: from 12–24 hpf, the hemo-
genic vascular niche is established, and from 24–36 hpf, post-
circulation onset, HSCs are specified and begin to bud from HE
in the artery. E2 exposure during these discrete time windows
caused a biphasic effect: treatment from 12–23 hpf resulted
in the absence of runx1/cmyb expression, whereas treatment
from 26–36 hpf increased HSPCs (Figure 3A); DPN mimicked
both aspects of this phenotype, suggesting each was mediated
by esr2 (Figure S4A). As the negative impact of E2 from 12–24
hpf was the dominant phenotype, we sought to further charac-
terize effects on the development of the hemogenic vascular
niche. Analysis of embryos expressing GFP under control of
the angiopoietin receptor promoter, tie2 (Tg(Tie2:EGFP), indi-
cated normal circulation and proper formation of the dorsal
aorta and cardinal vein after E2 exposure (Figure 3B); in
contrast, tie2:GFP+ intersomitic vessels (ISVs) were strongly
reduced. Expression of the VEGF receptor flk1 (kdrl, VEGFR2)
was decreased in the major vessels of most E2-exposed em-
bryos, with ISV expression reduced or absent at 36 hpf, as
confirmed by qPCR (Figures 3C and 3H; p < 0.01); however,
flk1+ cell number, as seen by FACS of the flk1:GFP line
(Tg(kdrl:EGFP) was not significantly altered (Figure 3G), confirm-
ing gross vascular structure was unaffected by exogenous E2.
To determine if reductions in flk1+ ISVs were indicative of defec-
tive vessel maturation, markers of artery-vein specification were
examined: WISH and qPCR showed ephrinB2 was robustly
decreased, whereas flt4, a venous marker, increased (Figures
3D, 3E, and 3H; ephrinB2 p < 0.001; flt4 p < 0.05). To assess
if the subset of HE was negatively impacted, scl-expressing
cells in the transgenic Tg(-6tal1:EGFP) reporter were examined:
following E2-exposure, arterial expression of scl was almost ab-
sent, as confirmed by qPCR (p < 0.05) (Figures 3F and 3H). To
determine if scl loss was responsible for the dramatic reduction
in HSPCs, E2-treated embryos were injected with scl mRNA
(Figure 3I); whereas 86% of E2-exposed embryos showed
runx1 loss, scl-injection rescued expression in 77% of treated
embryos. Together, these data indicate E2 alters the production
HSPCs via regulation of aortic vessel maturation and tissue
specification.
As early E2 exposure had a potent negative effect on HE, we
sought to determine if the later effects of E2 on HSPCs were
likewise due to niche regulation. A positive response to E2
treatment from 26–36 hpf was confirmed by qPCR for runx1
and cmyb (Figure S4B; p < 0.05), but no impact was found
on ephrinB2 or flt4 (data not shown), suggesting at later stages
E2 may act directly on HSPCs. As E2 is a known cell-cycle
regulator, several indicators of proliferation were examined:
both cyclinD1 and cmyc were increased by E2 exposure
from 26–36 hpf (Figure S4C, cyclinD1 p < 0.01, cmyc p <
0.001); phosphohistone H3 (Figure S4D, p < 0.01) and BrdU
incorporation (Figure S4E) were similarly enhanced, together
indicating elevations in runx1+ HSPCs, following later E2 treat-
ment, coincide with increased cell proliferation, consistent with
recent reports (Nakada et al., 2014). In contrast, BrdU was not
altered by early E2 exposure. These data indicate E2 onlyc.
Figure 2. ERE:GFP Embryos Display Estrogen Activity in the Developing AGM
(A) MO knockdown showed that the effect of E2 on HSPCs is mediated through esr2a+b; esr1-MO had no impact on runx1/cmyb (nR 30).
(B) ERE:GFP embryos show low expression in the trunk vasculature, labeled by lmo2:dsRed; ERE activity expands following E2 exposure and is alleviated by
treatment with ZK164015 (nR 20).
(C) ERE:GFP embryos exhibit activity in the developing mesonephros, as indicated by cdh17:mCherry at 48 hpf, which responds to altered E2 signaling (nR 20).
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Figure 3. E2 Exposure Impairs Formation of the Hemogenic Endothelial Niche
(A) E2 had a biphasic effect onHSPCs: treatment during hemogenic niche specification (12–23 hpf) decreased runx1, whereas exposure during HSC specification
and budding (26–36 hpf) increased HSPCs (nR 75/treatment).
(B) Treatment with E2 had no impact on axial vessel formation as assessed by tie2:GFP (nR 20).
(C) E2 disrupts ISV formation as indicated by flk1 WISH (59/70).
(legend continued on next page)
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independent of proliferation, implying it plays a role in speci-
fying HE.
E2 Exposure Disrupts the VEGF/Notch Pathway,
Leading to Vascular Defects
Specification of the arterial trunk vasculature, where the hemo-
genic vascular endothelium is located, occurs through precise
stepwise induction of known signaling pathways: Hedgehog
(HH), Vascular Endothelial Growth Factor (VEGF), and Notch
(Lawson et al., 2001, 2002). As Notch was the most proximal
to HSCs, it was tested for response to E2 exposure. At 18 hpf,
after 6 hr of treatment, no changes in global expression of the
Notch ligand deltaC were noted, indicating Notch signaling initi-
ates correctly (Figure 4A); this finding was corroborated using
Notch:GFP (Tg(EPV:Tp1-MmuHbb:EGFP)) reporter embryos
(Parsons et al., 2009) and ephrinB2 WISH (Figures S5A and
S5B). At 24 and 36 hpf, however, marked decreases in arterial
deltaC expression were observed, as confirmed by qPCR
(Figures 4A and 4C; p < 0.05); a similar pattern of regulation
was observed for notch3 (Figures 4B and 4C; p < 0.05). The
Notch:GFP reporter likewise showed strongly reduced arterial
and intersomitic activity (Figure 4D); inhibition was also noted
for the notch target hey2 and the VEGF-regulated arterial marker
and notch pathway component notch1b (Figures S5C and S5D).
Hyperactivation of the Notch pathway, downstream of ligand
binding, was used to determine if restoration of Notch signaling
could rescue E2-mediated HSPC defects. Heat shock induction
of the Notch intracellular domain (NICD) (hs:Gal4; UAS:NICD) in
controls resulted in increased runx1 expression in both the artery
and the vein (23/37), matching published results (Burns et al.,
2005), whereas NICD activation in E2-treated fish recovered
runx1+ HSPCs (20/31) (Figure 4E). mindbomb (mib) mutants
have defective Notch signaling (Itoh et al., 2003); mib+/ em-
bryos, compared to controls, showed a previously unreported
reduction in runx1 expression (Figure S5E), which was exacer-
bated after E2 treatment (22/41), mimicking the homozygous
phenotype. These data indicate synergy between E2 exposure
and loss of Notch activity and imply deficits in Notch signaling
cause HSPC abnormalities induced by exogenous E2.
VEGF acts upstream of Notch in vascular specification.
E2 exposure caused decreased somitic expression of VEGFAa
at both 18 and 24 hpf, as confirmed by qPCR (Figures 4F
and 4G; p < 0.001). Heat-shock-inducible VEGFAa embryos
(hs:VEGFAa [Wiley et al., 2011]) were utilized to determine if
hyperactivation of VEGF could rescue E2-mediated HSPC de-
fects. VEGFAa induction increased runx1 (31/37) in controls (Fig-
ure 4H), consistent with our recent observations (Harris et al.,
2013) and compensated for the deleterious effect of E2 (16/
33). However, when Notch activity was simultaneously blocked
by the g-secretase inhibitor DAPT (20 mM), VEGF overexpression(D) Arterial ephrinb2 was robustly decreased by E2 (77/80); red arrowheads indic
(E) Venous flt4 was increased after E2 exposure (40/53).
(F) scl:GFP was reduced by E2 treatment (25/30).
(G) FACS of flk1:GFP+ embryos (n = 32) revealed no change in endothelial cell n
(H) qPCR confirmed decreased expression of flk1, ephrinB2, and scl following E2 t
flk1 **p < 0.01, and ephrinB2 ***p < 0.001).
(I) Injection of scl mRNA increased runx1 expression in the AGM and rescued los
Devefailed to rescue the effect of E2 on HSPCs (38/38) (Figure 4H);
this Notch dependence was confirmed by Notch:GFP WISH,
where increased activity was observed following VEGF induction
(Figures S5F and S5G). tbx20 expression is unaffected in mib
mutants, indicating it is regulated upstream of Notch signaling
in arterial specification (Lawson et al., 2001). Arterial tbx20
was reduced by E2 (23/25); induction of VEGFAa in E2 treated
embryos partially rescued tbx20 expression (16/25), whereas
NICD could not (Figure S6A) (4/26). In contrast, effects of later
E2 exposure were independent of Notch or VEGF (Figures S4F
and S4G). To assess if HH-signaling, upstream of VEGF, was
also impacted by E2, we examined expression of shh and its
targets: shh was unaltered, whereas decreases in patched2
(ptch2) and GLI-Kruppel family member 1 (gli1) were observed
by qPCR (Figures S6B and S6C; *p < 0.05, **p < 0.01), although
no changes inmuscle or somite development were noted. To see
if E2-mediated HH regulation caused VEGFAa, loss, embryos
were treated with the smoothened agonist SAG: SAG enhanced
ptch2 expression and blunted the effects of E2. SAG likewise
enhanced VEGFAa in controls; however, it had no impact on
VEGFAa in E2-treated embryos, indicating E2 antagonizes
VEGF independently of HH (Figure S6D). Together, these data
suggest E2-mediated alterations in hemogenic niche specifica-
tion are caused by loss of VEGFAa expression and downstream
activity.
Xenoestrogens Partially Mimic the Effects of
17b-Estradiol on HSCs
To determine if estrogens could limit HSPC production in the
absence of deficiencies in maternal or fetal E2 regulation, we
examined the impact of environmentally derived xenoestrogens
(XE). Three compounds, genistein (GEN), a component of soy
products, ethinylestradiol (EE), an estrogen found in hormonal
contraceptives, and Bisphenol A (BPA), a hardening agent
used in the manufacturing of plastics, were selected as
representatives of the larger class of XEs. Upon XE treatment,
runx1/cmyb expression was reduced in all cases, as confirmed
by qPCR (Figures 5A and 5F). Importantly, XE-mediated HSPC
loss could be rescued by treatment with FULV, indicating the
effects were mediated, at least in part, by Esr signaling (Fig-
ure 5A). GEN and EE treatment also partially replicated the
vascular niche defects observed with E2: at nontoxic doses,
no major abnormalities were seen in ISV formation by fli1/flk1
staining (Figure 5B); however, arterial Notch:GFP was reduced
by both GEN and EE (Figure 5C). Exposure to GEN and EE like-
wise led to alterations in arterial marker expression and expres-
sion of scl, whereas BPA had no effect on these targets (Figures
5E and 5F). Further, a noticeable reduction in VEGFAa expres-
sion was caused by EE (Figure 5D). Whereas changes following
XE treatment were neither as severe nor as penetrant as those
from excess E2, the same signaling cascades were affected,ate artery, and blue arrowheads indicate vein.
umber by E2 (error bars indicate SD).
reatment (mean of triplicate experiments ± SEM; one-tailed t test; flt4 *p < 0.05,
s following E2 treatment (n > 55 per treatment).
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Figure 4. Exogenous E2 Signaling Disrupts VEGF/NOTCH Cascades in the AGM
(A) E2 exposure had no impact on deltaC expression byWISH at 18 hpf but strongly reduced arterial expression at 24 and 36 hpf (n > 30/treatment); an arrowhead
indicates artery.
(B) Expression of notch3 was similarly regulated by E2 at 18, 24, and 36 hpf (n > 30/treatment); an arrowhead indicates artery.
(C) qPCR confirmed E2-mediated reductions in deltaC and notch3 expression at 36 hpf (mean of triplicate experiments ± SEM; one-tailed t test deltaC, notch3
*p < 0.05).
(D) Decreased Notch:GFP was observed in the artery (white bracket indicates artery walls) after E2 treatment from 12–36 or 12–23 hpf; no change occurred with
exposure from 26–36 hpf (nR 52).
(legend continued on next page)
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specification.
Antagonism of Estrogen Signaling Expands the Zone of
VEGF Regulation
Having determined exogenous E2 and related XEs negatively
impact HSC development via inhibition of the VEGF/Notch
cascade and subsequent formation of HE within the aortic
vasculature, we next wanted to see if intrinsic levels of E2 play
a functional role in niche specification. In contrast to excess
E2, embryos exposed to the pan-Esr antagonist ZK showed
increased somitic expression of VEGFAa at 24 hpf (Figure 6A);
downstream Notch:GFP activity was also enhanced by ZK (Fig-
ure S7F). In other species, both Notch and VEGF familymembers
contain functional EREs (Buteau-Lozano et al., 2002; Soares
et al., 2004); however, no consensus EREs were observed up
to 8 kb from the zebrafish VEGF transcriptional start site (data
not shown). To confirm that nascent E2 could nevertheless regu-
late VEGF activation, we examined embryos expressing GFP un-
der the regulation of 1.2 kb of the VEGF promoter (He and Chen,
2005) (Figure 6B); E2 strongly reduced VEGF activation, whereas
ZK broadened the zone of expression. To determine if VEGF
activity was also impacted, known transcriptional targets dll4,
dusp5, and notch1b (Bellou et al., 2009; Liu et al., 2003) (Figures
6C, 6D, and S7C)were assessed: inhibition of E2-signaling by ZK
strongly enhanced expression of each VEGF target compared to
controls, suggesting VEGF-mediated transcriptional regulation
is actively antagonized by endogenous E2 in hematovascular
development. Consistent with that finding, ZK-treated embryos
exhibited phenotypes reminiscent of those observed with
VEGF overexpression in the ventral aspect of the AGM, including
widening of the major vessels and ectopic or disorganized ISV
sprouting (Figures S7A and S7B) (Lawson et al., 2002; Wiley
et al., 2011).
Endogenous E2 in the yolk is spatially positioned in a loca-
tion proximal and just ventral to that of the developing AGM.
To determine if antagonism of VEGF activity by nascent E2
impacted dorsal/ventral patterning of trunk vasculature, we
next examined the boundaries of artery-vein specification
following Esr antagonism. Whereas ephrinB2 within the fli1+
endothelial population was reduced by exogenous E2, it was
noticeably enhanced by ZK treatment (Figure 6E); similar results
were observed with deltaC and the Notch target hey2 (Figures
S7D and S7E). Expression of VEGF-regulated tbx20was likewise
increased by ZK, including expansion to both walls of the aorta
from its characteristic position on the roof (Wilkinson et al.,
2009) (Figure 6F); enhanced arterial marker expression was
confirmed by qPCR (Figure S7K; *p < 0.05, **p < 0.01). In
contrast, whereas the dorsal limit of venous flt4 was heightened
by E2 toward the col2a+ hypochord, within the arterial space,
expression was diminished and patchy in embryos exposed to
ZK (Figure 6G). Identical findings were observed for dab2, where
reduced expression was seen in the vein after ZK treatment (Fig-(E) NICD induction increased expression of runx1/cmyb and rescued HSPCs in E
(F) Expression of VEGFAawas strongly decreased in zebrafish following E2 treatm
(G) qPCR confirmed that expression of VEGFAa was decreased at 24 hpf (mean
(H) Induction of VEGFAa increased runx1 expression and rescued the effect of E2 e
VEGF-mediated rescue of HSPCs (nR 20/treatment); an arrowhead indicates a
Deveure 6H), indicating the zone of VEGF-regulation was affected by
modulation of E2 activity.
Loss of E2-MediatedVEGFRegulationAltersHemogenic
Potential of the Vein
Hemogenic vascular endothelium is normally situated within ar-
teries, such as the dorsal aorta; we next sought to determine if
loss of E2-mediated antagonism of VEGF activity would be suf-
ficient to convert the functional potential of venous endothelium.
Expression of the HE marker scl was elevated in ZK treated
embryos, with induction in the vein in a subset of embryos (Fig-
ure S7G). This result was confirmed using scl:GFP/flk1:dsRed
embryos where ZK increased the number of double positive
vascular cells (Figure 7A). Arterial runx1 expression was also
increased via ZK (Figures 7B and 7D; *p < 0.05) and localized
to the vein in some embryos. This phenotype, reminiscent
of that previously reported for NICD (Burns et al., 2005), was
also seen after genetic suppression of esr2 signaling via MO
knockdown (Figure S7I). Although reassignment of arterial fate
as marked by ephrinB2 (Figure 6E) was not observed with
ZK, the percentage of embryos with venous runx1 expression
was proportional to those exhibiting Notch:GFP in the vein (Fig-
ure S7F); this finding was congruent with scl mRNA-mediated
recovery of HSPCs following E2 exposure, where runx1 expres-
sion was restored (Figure 3I) in the absence of ephrinB2 rescue
(Figure S7J). To confirm that alterations in E2 signaling had
functional consequences for HSC production, we assessed
HSC content using CD41:GFP+ and flk1:dsRed+/cmyb:GFP+
embryos, previously shown to contain functional HSCs by em-
bryo-to-adult transplantation (Harris et al., 2013) and lineage
tracing (Bertrand et al., 2010), respectively. Following ZK expo-
sure, the number of mature CD41:GFP+ HSCs in the AGM re-
gion was significantly increased (Figures 7E and S7H; p <
0.05). Analysis of flk1:dsRed+/cmyb:GFP+ cells budding from
the trunk vasculature was similarly elevated (Figures 7C and
7F). To demonstrate that the increase in HSPCs mediated by
ZK was due to elevated VEGF activity, we utilized previously
described VEGF pathway mutants: kdrly17 embryos exhibit
normal vasculogenesis but defective VEGF-mediated ISV
sprouting, whereas plcg1y13 mutants show no ISV production,
indicative of a block of increasing severity in VEGF activity
(Covassin et al., 2009). Control and ZK-treated embryos were
sorted based on fli1:GFP+ ISV expression (Figure S7L). kdrly17
mutants displayed reduced runx1 expression; however, ZK
exposure boosted HSPC number as determined by WISH (Fig-
ure 7G). In contrast, whereas plcg1y13 mutants also displayed a
virtual absence of runx1+ expression, the block in HSPC forma-
tion could not be alleviated by ZK (Figure 7H), indicating VEGF
activity was the target of E2 regulation. These data lead to a
model (Figure 7I) whereby maternally deposited E2 functions
to pattern the HSC niche via antagonism of the ventral limit of
VEGF regulation, allowing for the ‘‘appropriate’’ assignment of
HE and subsequent HSPC production.2-treated embryos (nR 31/treatment).
ent at both 18 and 24 hpf (nR 25/treatment); an arrow points to somite staining.
of triplicate experiments ± SEM; one-tailed t test ***p < 0.001).
xposure; treatment with DAPT decreased expression of runx1 and blocked the
rtery.
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Figure 5. Xenoestogens Partially Replicate the Effects of E2 on HSPC Formation
(A) Exposure to xenoestrogens ethinyl estradiol (EE), genistein (GEN), or Bisphenol A (BPA) decreased runx1/cmyb expression and could be partially blocked by
cotreatment with FULV (nR 25/treatment).
(B) Treatment with GEN reduced the expression of fli1/flk1 in the intersomitic vessels (nR 25/treatment); an arrow points to ISVs.
(C) Treatment with GEN (15/25) and EE (12/23) decreased Notch:GFP expression.
(legend continued on next page)
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In this paper, we identify estrogens as previously uncharacter-
ized regulators of embryonic hematovascular niche patterning.
Estrogens are considered the most ancient of the steroid
hormones and have remarkable ability to act as morphogens,
signaling molecules and transcription factors simultaneously,
thus controlling a myriad of downstream processes through a
combination of their relative concentration, receptor distribution,
and availability of direct genetic targets (Heldring et al., 2007;
Thornton, 2001). We propose that in zebrafish embryos (Fig-
ure 7I, top panel), endogenous E2 maternally deposited in the
yolk diffuses to define the ventral boundary of somite-derived
VEGF regulation. The opposing dorsal-ventral gradients result
in the artery receiving higher VEGF and lower E2 relative to the
vein and enables ‘‘proper’’ vasculature patterning with coinci-
dent localization of the hemogenic vascular niche to the artery.
When embryos are exposed to excess levels of E2 (Figure 7I,
middle panel), or related XEs, the gradient is disrupted and
additional estrogen is present to antagonize the VEGF/Notch
cascade in all cell types expressing Esrs. In this scenario, the
total region of VEGF (and Notch) activity decreases, leading
to loss of arterial markers in the developing vasculature, with a
concomitant enhancement in venous identity, and reductions
in HE specification. In contrast, when Esr signaling is inhibited
(Figure 7I, lower panel), the functional impact of the gradient of
E2 from the yolk is lessened, allowing the domain of VEGF regu-
lation to increase: expression of VEGF targets—including notch
components—are enhanced, repression of venous markers is
observed, and genes required for HE specification are elevated,
jointly causing occasional mislocalized production of runx1+
HSPCs in the vein independent of full arterial reassignment (Fig-
ure 7B). This study highlights the ability of E2 to act simulta-
neously as a morphogen, signaling molecule and (presumably)
transcription factor to pattern an embryonic niche outside of
the urogenital system. Further, this role in setting the limits of
VEGF regulation may help resolve discrepancies in the necessity
of arterial gene expression for hemogenic HSPC production.
Fine-tuned regulation of estrogen availability during early
development is highly conserved in placental mammals:
maternal estrogen levels are quite low early in pregnancy but
steadily increase until delivery (Tulchinsky et al., 1972). Our
data suggest that E2 levels may be actively suppressed during
early embryonic development in part to avoid negative impact
on vasculature specification and maturation, including HE
localization. Although there are clear anatomical differences be-
tween yolk-supported and placental vertebrate embryos, recent
studies have indicated that gene networks and cellular move-
ments establishing vascular progenitor fate are VEGF concentra-
tion dependent (Kohli et al., 2013) and more similar across
species than previously appreciated (Lindskog et al., 2014).
Beyond myeloproliferative disorders in a subset of adults, few
hematopoietic phenotypes have been noted, thus far, in mice
with homozygous Esr1 or Esr2 mutations (Krege et al., 1998;(D) VEGFAa was noticeably decreased by EE (15/26); arrowheads indicate somi
(E) Summary of changes in the expression of markers of vascular identity ephrin
(F) qPCR confirmed decreases in runx1, cmyb notch3, and scl by XE expo
**p < 0.01).
DeveLubahn et al., 1993); this finding is consistent with our data
indicating that early esr2 antagonism enhances, rather than
negatively impacts, HSPC production. Likewise, our observa-
tions concerning exposure to exogenous E2 are reminiscent
of prior reports of intrauterine hemorrhaging and eventual
death observed in embryos of Steroid 5a-Reductase-deficient
dams, which have maternally derived elevations in E2 (Mahend-
roo et al., 1997); in future studies, it will be interesting to specif-
ically examine how E2 modulation impacts hemogenic vascular
endothelial specification and HSC induction in mammalian
models.
In zebrafish, we can attribute the negative impact of exoge-
nous E2 on HSC formation to repression of VEGF-Notch
signaling during thewindowof hemogenic endothelium develop-
ment. Although E2 has long been recognized as having the ability
to modulate both VEGF and NOTCH expression in other con-
texts, its impact on the development of the hematovascular sys-
tem during embryogenesis is unique. Indeed, whereas ERE sites
in NOTCH and VEGF are functional in mammals, most evidence
from breast cancer studies suggests that E2 acts to induce both
pathways rather than repress them, as we observed (Buteau-
Lozano et al., 2002; Soares et al., 2004). Notably, however, E2
has been reported to antagonize VEGF signaling in hypoxic con-
ditions (Miyamoto et al., 2002). Although we found no evidence
of a consensus ERE in the VEGF promoter up to 8 kb from the
start site (data not shown), increasing evidence suggests the he-
matopoietic niche is a hypoxic environment in the embryo and
adult; we recently showed Hypoxia-Inducible Factor 1 alpha
(HIF1a) is a critical regulator of hematopoietic development (Har-
ris et al., 2013). Additional studies will be needed to determine
whether hypoxia and/or the HIF complex are interacting with
E2 in this context to directly or indirectly impactVEGF production
and downstream function. Our findings on the timing of E2-medi-
ated HE regulation indirectly support the hypoxia model, as the
negative impact of E2 on VEGF is only observed prior to the start
of circulation and maturation of oxygen-carrying erythrocytes
beginning at 24 hpf. It will be important to determine if transition-
ing out of this relatively hypoxic state postcirculation onset is the
reason E2 displays differential effects in later hematovascular
development. Also of potential consequence to the findings re-
ported here, recent investigations in Xenopus indicate different
VEGF isoforms are required for the establishment of arterial
versus hemogenic fate during development (Leung et al.,
2013); although it has not yet been demonstrated whether this
will also be the case in zebrafish or mammalian embryos, it will
be valuable to determine if estrogens could play a role in tran-
script selectivity.
Finally, the observation that common XEs, such as genistein
and ethinylestradiol, can similarly impact vascular patterning
and the subsequent specification of HSPCs suggests environ-
mentally relevant estrogenic substances may have an unex-
pected impact on hematovascular development in vivo.
Although the XEs tested were not as potent as E2, as a group
they are present at increasingly elevated concentrations in ourte region.
B2, flt4, notch3, and deltaC following treatment with XEs (nR 25).
sure (mean of triplicate experiments ± SEM; one-tailed t test *p < 0.05;
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Figure 6. Blocking Esr Signaling Increases VEGF Activity and Alters Trunk Vasculature Patterning
(A) VEGFAa expression was enhanced after inhibition of endogenous estrogen activity via the pan-Esr antagonist ZK164015 (18/32).
(B) gfp expression in VEGF:GFP reporter embryos was reduced by E2 and enhanced by ZK (n > 25).
(C) The VEGF target gene dll4 was decreased after E2 exposure but increased by ZK (n > 20).
(D) dusp5 levels were reduced by E2 treatment but elevated after Esr antagonism (n > 20).
(legend continued on next page)
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have had difficulty activating zebrafish Esrs at a level sufficient
to elicit a major response, as differences in receptor affinity
compared with endogenous E2 have been previously described
(Barkhem et al., 1998). The fact that XEs could affect the HSC
niche raises important questions about the long-term deleterious
effects of in utero exposure on hematopoietic development and
homeostasis. Although not specifically examined here, pregnant
mice fed a diet rich in genistein had pups with increased erythro-
poiesis and granulopoiesis at 12 weeks of age (Vanhees et al.,
2011). Genistein can also induce rearrangements in the Mixed
Lineage Leukemia (MLL) gene in humanCD34+ cells, resembling
those commonly seen in infant leukemias (Barjesteh van Waal-
wijk van Doorn-Khosrovani et al., 2007), and epidemiological
studies show exposure to dietary flavonoids during pregnancy
is linked to infant leukemia development (Ross, 2000). Our
data indicate that concentration and timing may significantly
alter the outcome of estrogenic exposure.
There is increasing evidence that hematopoietic cells continue
to be responsive to estrogenic regulation throughout their life-
time. During gestation, maternal blood volume grows by 50%
to accommodate the growing oxygenation and nutritional needs
of the fetus (Hytten, 1985), with recent investigations indicating
this is due in part to E2-mediated enhancement in HSPC prolif-
eration (Nakada et al., 2014). Further, guinea pigs administered
exogenous E2 showed increased blood volume comparable to
that seen during pregnancy, indicating it may be a critical regu-
lator of hematopoietic output in sexually mature adults (Davis
et al., 1989). Reduced E2 levels, as a result of ovariectomy in
rats, can lead to hematopoietic dysfunction, characterized by
increased extramedullary hematopoiesis (Qiu et al., 2012). How-
ever, exposure to excess E2 has also been associated with alter-
ations in hematopoietic cell number (Perry et al., 2000). Together
with our data, these studies indicate E2 regulates of several
aspects of hematopoiesis and suggest spatiotemporal alter-
ations in concentration of this previously underappreciated, but
well conserved, molecule will have significant impact beyond
embryogenesis. Here, we specifically demonstrate maternally
derived E2 has a central role in establishing dorsal-ventral
patterning of the hematovascular system, acting as a ventral-
limiting factor to specify the hemogenic vascular niche.
EXPERIMENTAL PROCEDURES
Zebrafish Husbandry
Zebrafish were maintained in accordance with the Beth Israel Deaconess
Medical Center Institutional Animal Care and Use Committee protocols.
Zebrafish lines utilized were previously described and are listed in the Supple-
mental Experimental Procedures.
Chemical Treatments and Evaluation
Embryonic zebrafish exposures were performed from five somites until 36 hpf
in multiwell plates, unless otherwise specified. The following compounds
(Cayman Chemicals, unless otherwise indicated) were used: 17b-estradiol
(E2) (8–10 mM), 17a-estradiol (10 mM), 2,3-bis(4-hydroxyphenyl)propionitrile(E) Arterial ephrinB2 expression in the fli1+ vasculature was enhanced after ZK-m
(F) tbx20 expression in the roof of the aorta was substantially increased by ZK (2
(G) Venous flt4 was expanded dorsally toward the col2a+ hypocord by E2 but re
(H) The venous marker dab2 was similarly regulated as determined by WISH (n >
Deve(DPN) (10 mM), propylpyrazole triol (PPT) (20 mM), fulvestrant (FULV; ICI-
182,780) (15 mM), genistein (GEN) (7.5 mM), ethinyl estradiol (EE) (6 mM),
bisphenol A (BPA) (30 mM [Sigma]), DAPT (GSI-IX) (20 mM), G1 (1 mM), G15
(10 mM), ZK164015 (ZK) (10 mM [Tocris]), SAG (10 mM), SU1498 (10 mM [Calbio-
chem]), and screen hits (10 mM). WISH was performed using previously pub-
lished probes and methods (http://zfin.org/ZFIN/Methods/ThisseProtocol.
html). Qualitative phenotypes (R3 replicate clutches) were scored as the
number altered/number analyzed per treatment. plcg1y13/y13 and kdrly17/y17
mutants were identified posttreatment, and evaluated by genotyping as
previously described (Covassin et al., 2006, 2009). FACS analysis of
transgenic lines (pools of three embryos 3 >10 biological replicates), phos-
pho-Histone H3 (pHH3) labeling (Abcam), and 5-bromo-20-deoxyuridine
(BrdU) incorporation (Sigma) were performed as previously described (Harris
et al., 2013; North et al., 2007). Images were acquired using a Zeiss Axio
Imager A1 or Zeiss Discovery V8/Axio Cam MRC and Axiovision LE software
(Carl Zeiss).
Morpholino and mRNA Injections
MOs (Supplemental Experimental Procedures; Gene Tools) were injected into
one-cell-stage embryos and treated and analyzed as detailed above; the
ERE:GFP line was used to confirm specificity. scl mRNA was synthesized
using the manufacturer’s directions for Ambion mMessage mMachine as pre-
viously described (Kim et al., 2013) and injected (150 pg) into one-cell-stage
embryos. Treatments and analysis were performed as described above.
Quantitative Real-Time PCR
RNA was isolated from pooled (n = 30) embryos at 24 or 36 hpf and isolated
using an RNAqueous Kit (Ambion). cDNA was made using the SuperScript III
First-Strand Synthesis kit (Invitrogen). qPCR reactions (primers listed in the
Supplemental Experimental Procedures) were performed using an ABI 7900
machine and analyzed as previously described (North et al., 2007) using the
ddCt method with either 18s or tbp as the reference gene.
Heat Shock Modulation of Notch and VEGF Signaling
Embryos were treated with test compounds prior to and post-heat shock as
indicated. hs:VEGFAa and hs:Gal4 x UAS:NICD expression was induced by in-
cubation in a 38C circulating water bath for 10 or 7 min, respectively, at 16
hpf. hs:VEGFAa fish were identified by cardiac GFP expression, and hs:Gal4 x
UAS:NICD fish were identified by genotyping post-WISH analysis.
Estradiol Immunoassay
E2 content was measured using an Estradiol EIA Kit (Cayman Chemical). Em-
bryos (n = 30) were pooled and homogenized in 100 ml of EIA buffer and diluted
to 300 ml total volume; 50 ml was used per reaction in accordance with the
manufacturer’s instructions. For yolk content analysis, the yolk was manually
removed by pipetting (10 ml tip), and embryos were pelleted for 30 s at
300 rpm. Yolk extract (supernatant) was collected, and the pellet (body) was
disaggregated and resuspended in 300 ml EIA buffer as above. Analysis was
performed in accordance with instructions from Cayman Chemical.
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Figure 7. E2-Mediated VEGF Antagonism Regulates Hemogenic Endothelial Specification
(A) Hemogenic endothelium, as assessed by the dual expression of scl:GFP and flk1:dsRed, was reduced by exogenous E2 treatment but was enhanced
following Esr antagonism by ZK (n > 15).
(B) runx1 expression increased (27/54) after estrogen receptor inhibition, with mislocalization to the vein (10/54).
(C) Production of flk1:dsRed+; cmyb:GFP+ HSCs was enhanced by ZK (nR 10).
(legend continued on next page)
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